Survival benefit of boron neutron capture therapy for recurrent malignant gliomas

Shin Ichi Miyatake; Shinji Kawabata; Kunio Yokoyama; Toshihiko Kuroiwa; Hiroyuki Michiue; Yoshinori Sakurai; Hiroaki Kumada; Minoru Suzuki; Akira Maruhashi; Mitsunori Kirihata; Koji Onoc

doi:10.1016/j.apradiso.2009.03.032

Survival benefit of boron neutron capture therapy for recurrent malignant gliomas

Shin Ichi Miyatake, Shinji Kawabata, Kunio Yokoyama, Toshihiko Kuroiwa, Hiroyuki Michiue, Yoshinori Sakurai, Hiroaki Kumada, Minoru Suzuki, Akira Maruhashi, Mitsunori Kirihata, Koji Onoc

Neutron Therapy Research Center

Research output: Contribution to journal › Article › peer-review

13 Citations (Scopus)

Abstract

We have applied boron neutron capture therapy (BNCT) to malignant brain tumors. Here we evaluated the survival benefit of BNCT for recurrent malignant glioma (MG). Since 2002, we have treated 22 cases of recurrent MG with BNCT. Survival time was analyzed with special reference to recursive partitioning analysis (RPA) classification, by Carson et al. Median survival times (MSTs) after BNCT for all patients and for glioblastoma as on-study histology at recurrence was 10.8 months (n=22; 95% CI, 7.3-12.8 months) and 9.6 months (n=19; 95% CI, 6.9-11.4 months), respectively. In our study, MST for the high-risk RPA classes was 9.1 months (n=11; 95% CI, 4.4-11.0 months). By contrast, the original journal data showed that the MST of the same RPA classes was 4.4 months (n=129; 95% CI, 3.6-5.4 months). BNCT showed a survival benefit for recurrent MG, especially in the high-risk group.

Original language	English
Pages (from-to)	S22-S24
Journal	Applied Radiation and Isotopes
Volume	67
Issue number	7-8 SUPPL.
DOIs	https://doi.org/10.1016/j.apradiso.2009.03.032
Publication status	Published - Jul 1 2009

Keywords

Boronophenylalanine PET
Glioblastoma
Malignant glioma
Recursive partitioning analysis (RPA)

ASJC Scopus subject areas

Radiation

Access to Document

10.1016/j.apradiso.2009.03.032

Fingerprint Dive into the research topics of 'Survival benefit of boron neutron capture therapy for recurrent malignant gliomas'. Together they form a unique fingerprint.

Cite this

Survival benefit of boron neutron capture therapy for recurrent malignant gliomas. / Miyatake, Shin Ichi; Kawabata, Shinji; Yokoyama, Kunio; Kuroiwa, Toshihiko; Michiue, Hiroyuki; Sakurai, Yoshinori; Kumada, Hiroaki; Suzuki, Minoru; Maruhashi, Akira; Kirihata, Mitsunori; Onoc, Koji.

In: Applied Radiation and Isotopes, Vol. 67, No. 7-8 SUPPL., 01.07.2009, p. S22-S24.

Research output: Contribution to journal › Article › peer-review

Miyatake, Shin Ichi ; Kawabata, Shinji ; Yokoyama, Kunio ; Kuroiwa, Toshihiko ; Michiue, Hiroyuki ; Sakurai, Yoshinori ; Kumada, Hiroaki ; Suzuki, Minoru ; Maruhashi, Akira ; Kirihata, Mitsunori ; Onoc, Koji. / Survival benefit of boron neutron capture therapy for recurrent malignant gliomas. In: Applied Radiation and Isotopes. 2009 ; Vol. 67, No. 7-8 SUPPL. pp. S22-S24.

@article{cf12627924194216a06b7dbbf2f52715,

title = "Survival benefit of boron neutron capture therapy for recurrent malignant gliomas",

abstract = "We have applied boron neutron capture therapy (BNCT) to malignant brain tumors. Here we evaluated the survival benefit of BNCT for recurrent malignant glioma (MG). Since 2002, we have treated 22 cases of recurrent MG with BNCT. Survival time was analyzed with special reference to recursive partitioning analysis (RPA) classification, by Carson et al. Median survival times (MSTs) after BNCT for all patients and for glioblastoma as on-study histology at recurrence was 10.8 months (n=22; 95% CI, 7.3-12.8 months) and 9.6 months (n=19; 95% CI, 6.9-11.4 months), respectively. In our study, MST for the high-risk RPA classes was 9.1 months (n=11; 95% CI, 4.4-11.0 months). By contrast, the original journal data showed that the MST of the same RPA classes was 4.4 months (n=129; 95% CI, 3.6-5.4 months). BNCT showed a survival benefit for recurrent MG, especially in the high-risk group.",

keywords = "Boronophenylalanine PET, Glioblastoma, Malignant glioma, Recursive partitioning analysis (RPA)",

author = "Miyatake, {Shin Ichi} and Shinji Kawabata and Kunio Yokoyama and Toshihiko Kuroiwa and Hiroyuki Michiue and Yoshinori Sakurai and Hiroaki Kumada and Minoru Suzuki and Akira Maruhashi and Mitsunori Kirihata and Koji Onoc",

year = "2009",

month = jul,

day = "1",

doi = "10.1016/j.apradiso.2009.03.032",

language = "English",

volume = "67",

pages = "S22--S24",

journal = "Applied Radiation and Isotopes",

issn = "0969-8043",

publisher = "Elsevier Limited",

number = "7-8 SUPPL.",

}

TY - JOUR

T1 - Survival benefit of boron neutron capture therapy for recurrent malignant gliomas

AU - Miyatake, Shin Ichi

AU - Kawabata, Shinji

AU - Yokoyama, Kunio

AU - Kuroiwa, Toshihiko

AU - Michiue, Hiroyuki

AU - Sakurai, Yoshinori

AU - Kumada, Hiroaki

AU - Suzuki, Minoru

AU - Maruhashi, Akira

AU - Kirihata, Mitsunori

AU - Onoc, Koji

PY - 2009/7/1

Y1 - 2009/7/1

N2 - We have applied boron neutron capture therapy (BNCT) to malignant brain tumors. Here we evaluated the survival benefit of BNCT for recurrent malignant glioma (MG). Since 2002, we have treated 22 cases of recurrent MG with BNCT. Survival time was analyzed with special reference to recursive partitioning analysis (RPA) classification, by Carson et al. Median survival times (MSTs) after BNCT for all patients and for glioblastoma as on-study histology at recurrence was 10.8 months (n=22; 95% CI, 7.3-12.8 months) and 9.6 months (n=19; 95% CI, 6.9-11.4 months), respectively. In our study, MST for the high-risk RPA classes was 9.1 months (n=11; 95% CI, 4.4-11.0 months). By contrast, the original journal data showed that the MST of the same RPA classes was 4.4 months (n=129; 95% CI, 3.6-5.4 months). BNCT showed a survival benefit for recurrent MG, especially in the high-risk group.

AB - We have applied boron neutron capture therapy (BNCT) to malignant brain tumors. Here we evaluated the survival benefit of BNCT for recurrent malignant glioma (MG). Since 2002, we have treated 22 cases of recurrent MG with BNCT. Survival time was analyzed with special reference to recursive partitioning analysis (RPA) classification, by Carson et al. Median survival times (MSTs) after BNCT for all patients and for glioblastoma as on-study histology at recurrence was 10.8 months (n=22; 95% CI, 7.3-12.8 months) and 9.6 months (n=19; 95% CI, 6.9-11.4 months), respectively. In our study, MST for the high-risk RPA classes was 9.1 months (n=11; 95% CI, 4.4-11.0 months). By contrast, the original journal data showed that the MST of the same RPA classes was 4.4 months (n=129; 95% CI, 3.6-5.4 months). BNCT showed a survival benefit for recurrent MG, especially in the high-risk group.

KW - Boronophenylalanine PET

KW - Glioblastoma

KW - Malignant glioma

KW - Recursive partitioning analysis (RPA)

UR - http://www.scopus.com/inward/record.url?scp=67649389423&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649389423&partnerID=8YFLogxK

U2 - 10.1016/j.apradiso.2009.03.032

DO - 10.1016/j.apradiso.2009.03.032

M3 - Article

C2 - 19394240

AN - SCOPUS:67649389423

VL - 67

SP - S22-S24

JO - Applied Radiation and Isotopes

JF - Applied Radiation and Isotopes

SN - 0969-8043

IS - 7-8 SUPPL.

ER -